Dr Gerard McGlacken APC Faculty
Dr Gerard McGlacken obtained his B.Sc. and Ph.D at the National University of Ireland, Galway. He then moved to the University of York (UK) where his research interests diversified to organometallic transformations and molecules of biological importance with Prof. Ian J. S. Fairlamb. A year later, he took up a ‘Molecular Design and Synthesis Post-Doctoral Fellowship’ at Florida State University (US) working with Prof. Robert A. Holton on the total synthesis of the large polyether antibiotic lonomycin A. He obtained a Lectureship position at University College Cork in 2007 and a permanent position in 2011.
His current research is in the area of organic synthesis applied to biologically significant molecules. He collaborates with Dr Jerry Reen, Prof Fergal O’Gara, Dr Harriet Schellekens, Prof John Cryan and others in this space.
En route to biologically active compounds, novel methodology involving organometallic and asymmetric synthesis is employed.
Dr McGlacken has published over 60 independent articles in high impact journals such as Angew. Chem. Int. Ed., Org. Lett, Chem. Commun., Chem. Sci., ACS Catalysis and Chem. Eur. J. etc. His work has received over 1000 citations.
He has received over €2 million in competitive funding as part of the Science Foundation Ireland Research Frontiers Program (2009), the Investigators Program (2011) and others. He has also received two Technology and Innovation Development Awards (TIDA) from SFI.
He works closely with the Pharmaceutical Industry both in Ireland and the United States and has received grants with Eli Lilly (2010 & 2018) and Merck (2015) as part of the Enterprise Ireland Innovation Partnership program and the LRAP program. He also collaborates with the large Pharma company Syngenta and has placed PhD students in Basel, Switzerland. He has also worked with Pfizer as part of the Irish Research Council Industry Partnership Program, which resulted in the funding of two PhD positions.
He has been invited to give several international guest lectures, most recently at the 4th International Symposium in Yokohama, Japan, in August 2018.
Dr McGlacken is Vice-Chairman of the large EU COST Action: CH Activation in Organic Synthesis (CHAOS).
Finally, Dr McGlacken is a Funded Investigator within the SFI-funded Synthesis and Solid State Pharmaceutical Centre (SSPC) research centre and is associated with both AMBER (Advanced Materials and BioEngineering Research) and APC Microbiome Ireland.